Table 1

 Baseline characteristics of randomised population (ITT)

Placebo(n = 318)Salmeterol(n = 316)
Figures are mean (SD) unless otherwise stated.
BDP, beclomethasone dipropionate; LABA, long acting β agonist; FEV1, forced expiratory volume in 1 second.
*Continued into the treatment period.
Age (years)62.3 (9.1)62.4 (9.2)
Men, n (%)242 (76%)242 (77%)
Weight (kg)74.8 (16.53)75.7 (16.58)
Duration of COPD (years)11.1 (8.1)11.2 (8.4)
Smoking status, n (%)
    Current146 (46%)147 (47%)
    Ex-smoker172 (54%)169 (53%)
Pack years
    Current40.4 (18.2)40.7 (20.9)
    Ex-smoker39.6 (25.9)38.1 (21.5)
Patients who continued any COPD medication,* n (%)282 (89%)271 (86%)
Patients taking inhaled corticosteroids,* n (%)191 (60%)172 (54%)
Daily dose BDP (μg)345 (235)319 (240)
Daily dose fluticasone (μg)273 (191)266 (182)
Daily dose budesonide (μg)345 (215)383 (297)
Daily dose flunisolide (μg)450 (71)375 (177)
Patients taking LABA, n (%)71 (22%)69 (22%)
Patients taking anticholinergics,* n (%)181 (57%)168 (53%)
Patients taking xanthines,* n (%)133 (42%)138 (44%)
Patients receiving non-COPD medication,* n (%)135 (42%)126 (40%)
Baseline FEV1 (l)1.3 (0.5)1.3 (0.5)
FEV1 (% predicted)45.8 (14.1)46.1 (14.5)
Reversibility (% predicted value)2.9 (3.6)3.3 (3.6)